Turn Therapeutics Inc. (TTRX) - What Are Brokerages Thinking About This Stock?

Turn Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately bullish: Six research firms give Turn Therapeutics an average “Moderate Buy” rating, with an average 12-month price target of $9.00. Ratings include two strong buys, one buy, two holds, and one sell.
  • Institutional ownership has increased: Several investors recently initiated or expanded positions, including SteelPeak Wealth, which raised its stake by 0.7%, along with new holdings from BlackRock, Bridgewater Advisors, and Jefferies.
  • The company remains loss-making and financially leveraged: Turn Therapeutics reported a quarterly loss of $0.20 per share, while analysts expect a full-year loss of $0.40 per share. Shares opened at $9.65, with a debt-to-equity ratio of 8.83 and a 52-week range of $2.57 to $16.45.
  • MarketBeat previews top five stocks to own in December.

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.00.

A number of research firms have recently commented on TTRX. Zacks Research raised shares of Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. Wall Street Zen raised shares of Turn Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a "strong-buy" rating in a report on Monday, July 20th. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a "strong-buy" rating in a report on Thursday, September 24th. Finally, WBB Securities upgraded shares of Turn Therapeutics from a "sell" rating to a "hold" rating and set a $10.00 price objective on the stock in a report on Friday, October 23rd.

Check Out Our Latest Analysis on Turn Therapeutics

Institutional Trading of Turn Therapeutics

Institutional investors have recently modified their holdings of the company. SteelPeak Wealth LLC raised its stake in shares of Turn Therapeutics by 0.7% in the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company's stock valued at $3,616,000 after purchasing an additional 1,819 shares in the last quarter. Ieq Capital LLC acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at $1,660,000. BlackRock Inc. acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at $282,000. Bridgewater Advisors Inc. acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at $242,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Turn Therapeutics during the 2nd quarter worth about $119,000.

Turn Therapeutics Stock Performance

Shares of NASDAQ TTRX opened at $9.65 on Tuesday. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market cap of $294.61 million and a price-to-earnings ratio of -33.28. The business's 50-day simple moving average is $11.73 and its 200-day simple moving average is $7.04. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $16.45.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. As a group, equities research analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Turn Therapeutics Company Profile

(Get Free Report)

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company's platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.

Further Reading

Analyst Recommendations for Turn Therapeutics (NASDAQ:TTRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Turn Therapeutics Right Now?

Before you consider Turn Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.

While Turn Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines